Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.
The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.
Novo Nordisk’s Wegovy made a significant impact on the obesity market when it launched in 2021.
The approval of sotatercept came through the International Recognition Procedure.
HUTCHMED is set to gain a milestone payment from AstraZeneca.
The approval is underpinned by data from 15 clinical trials involving 800 healthy volunteers.
